These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25546733)

  • 1. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
    Mavinkurve-Groothuis AM; van den Heuvel-Eibrink MM; Tytgat GA; van Tinteren H; Vujanic G; Pritchard-Jones KL; Howell L; Graf N; Bergeron C; Acha T; Catania S; Spreafico F
    Pediatr Blood Cancer; 2015 Apr; 62(4):598-602. PubMed ID: 25546733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01.
    Graf N; van Tinteren H; Bergeron C; Pein F; van den Heuvel-Eibrink MM; Sandstedt B; Schenk JP; Godzinski J; Oldenburger F; Furtwängler R; de Kraker J
    Eur J Cancer; 2012 Nov; 48(17):3240-8. PubMed ID: 22795263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
    van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
    Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.
    Metzger ML; Stewart CF; Freeman BB; Billups CA; Hoffer FA; Wu J; Coppes MJ; Grant R; Chintagumpala M; Mullen EA; Alvarado C; Daw NC; Dome JS
    J Clin Oncol; 2007 Jul; 25(21):3130-6. PubMed ID: 17634492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 23-year experience with malignant renal tumors in infancy and childhood.
    Tröbs RB; Hänsel M; Friedrich T; Bennek J
    Eur J Pediatr Surg; 2001 Apr; 11(2):92-8. PubMed ID: 11371043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
    Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
    Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience.
    Hol JA; Jongmans MCJ; Sudour-Bonnange H; Ramírez-Villar GL; Chowdhury T; Rechnitzer C; Pal N; Schleiermacher G; Karow A; Kuiper RP; de Camargo B; Avcin S; Redzic D; Wachtel A; Segers H; Vujanic GM; van Tinteren H; Bergeron C; Pritchard-Jones K; Graf N; van den Heuvel-Eibrink MM;
    Cancer; 2021 Feb; 127(4):628-638. PubMed ID: 33146894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)".
    ; van den Heuvel-Eibrink MM; Pritchard-Jones K; van Tinteren H; Graf N
    Eur J Cancer; 2015 May; 51(8):995-6. PubMed ID: 25840668
    [No Abstract]   [Full Text] [Related]  

  • 11. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
    Stefanowicz J; Sierota D; Balcerska A; Stoba C
    Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
    Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.
    de Kraker J; Graf N; van Tinteren H; Pein F; Sandstedt B; Godzinski J; Tournade MF;
    Lancet; 2004 Oct 2-8; 364(9441):1229-35. PubMed ID: 15464183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
    Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
    Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols.
    Groenendijk A; van Tinteren H; Jiang Y; de Krijger RR; Vujanic GM; Godzinski J; Rübe C; Schenk JP; Morosi C; Pritchard-Jones K; Al-Saadi R; Vaidya SJ; Verschuur AC; Ramírez-Villar GL; Graf N; de Camargo B; Drost J; Perotti D; van den Heuvel-Eibrink MM; Brok J; Spreafico F; Mavinkurve-Groothuis AMC
    Eur J Cancer; 2022 Mar; 163():88-97. PubMed ID: 35042071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age is not a prognostic factor in children with Wilms tumor beyond stage I in Africa.
    Aronson DC; Hadley GP
    Pediatr Blood Cancer; 2014 Jun; 61(6):987-9. PubMed ID: 24453084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group.
    Furtwängler R; Nourkami N; Alkassar M; von Schweinitz D; Schenk JP; Rübe C; Siemer S; Leuschner I; Graf N
    Klin Padiatr; 2011 May; 223(3):113-9. PubMed ID: 21509706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of Wilms' tumour management in two tertiary-care hospitals in Asia.
    Sen S; Kadamba P; Al-AbdulAaly M; Mammen KE; Ahmed S
    Pediatr Surg Int; 1998 Jan; 13(1):42-4. PubMed ID: 9391203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat nephron-sparing surgery for children with bilateral Wilms tumor.
    Kieran K; Williams MA; McGregor LM; Dome JS; Krasin MJ; Davidoff AM
    J Pediatr Surg; 2014 Jan; 49(1):149-53. PubMed ID: 24439600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study.
    Hempel L; Kremens B; Weirich A; Graf N; Zintl F; Ludwig R
    Klin Padiatr; 1996; 208(4):186-9. PubMed ID: 8776705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.